产品名称

莫索尼定(Moxonidine)

一般描述

Moxonidine is a new generation centrally acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension.

别 称

4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine; Normoxocin

纯 度

≥99.0%(HPLC)

CAS NO.

75438-57-2

分子式

C⁹H¹²ClN⁵O

分子量

241.679

适用范围

生物试剂，适用于细胞培养等

l  理化信息

外 观

白色或类白色固体

溶解性(25℃)

DMSO

≥15mg/mL

乙醇

Very slightly soluble

水

Insolube

l  生物学信息

生物活性/药理作用

Moxonidine (INN) is a new generation centrally acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. Moxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). This receptor  subtype is found in both the rostral ventro-lateral pressor and ventromedial depressor areas of the medulla oblongata. Moxonidine therefore causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.

应 用

Antihypertensive Agents

l  存储

存储温度

-20℃

l  注意事项及免责声明

本产品仅用于实验研究，不得作为药物使用，不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.   https://www.ncbi.nlm.nih.gov